Skip to main content

Table 1 Baseline demographics and disease activity

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

  At baseline in ReAct At baseline in ReAlise
Parameter n Value n Value
Age, y, mean (SD) 6,610 53.7 (13.0) 3,435 54.5 (12.5)
Female, n (%) 6,610 5,332 (80.7) 3,435 2,724 (79.3)
Duration of RA, y, mean (SD) 6,572 10.8 (8.6) 3,423 12.0 (8.6)
Rheumatoid factor positive, n (%) 6,610 4,811 (72.8) 3,429 2,548 (74.2)*
DMARD use at baseline, n (%) 6,610 4,879 (73.8) 3,435 2,636 (76.7)*
SJC (28), mean (SD) 6,607 10.4 (5.8) 3,435 2.2 (3.4)
TJC (28), mean (SD) 6,607 13.5 (7.0) 3,435 3.2 (4.7)
PtGA, mm VAS, mean (SD) 6,568 61.9 (21.4) 3,256 26.2 (23.3)
DAS28 (ESR), mean (SD) 6,554 6.0 (1.1) 2,729 3.5 (1.3)
HAQ DI, mean (SD) 6,560 1.64 (0.68) 3,235 0.89 (0.74)
CRP, mg/L, mean (SD) 6,535 25.7 (30.8) 2,962 9.5 (15.7)
  1. *At time of entry into ReAct study. CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ DI, Health Assessment Questionnaire Disability Index; PtGA, patient global assessment; RA, rheumatoid arthritis; SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.